Phase III Clinical Trial

Related by string. Phase III clinical trials * phase . phases . Phases : Phase III trials . Phase 2b clinical . pivotal Phase III / iii . Iii . IIIs : Star Wars Episode III . Guitar Hero III . Tha Carter III / clinicals . CLINICAL . Clinicals : Phase III clinical . placebo controlled clinical trials . Clinical Excellence NICE / trialed . trialing : Week Premium Trial . randomized controlled trial * *

Related by context. All words. (Click for frequent words.) 87 Phase III Trial 86 Phase 2b Clinical Trial 86 Phase IIb Trial 85 Pivotal Phase III 85 Pivotal Trial 85 Meets Primary Endpoint 85 Pivotal Study 84 Clinical Trial Results 84 Patient Enrollment 83 Drug Candidate 83 Phase III Clinical Trials 83 Phase IIb Clinical Trial 83 Completes Patient Enrollment 83 Phase 2b Trial 83 Completes Enrollment 82 Phase 2a Clinical Trial 82 Phase III Trials 82 Pivotal Phase 81 NDA Submission 81 Single Dose 81 II Clinical Trial 81 Pivotal Clinical Trial 81 Receives Orphan Drug Designation 81 Demonstrates Positive 81 Phase 2b Study 80 Patients Treated With 80 Investigational Compound 80 Improves Survival 80 Initiates Phase III 80 JAK Inhibitor 80 Monotherapy 80 Files IND 80 Preclinical Data 80 Clinical Trial Evaluating 79 Study Evaluating 79 Phase 1b Clinical Trial 79 Phase 2a Trial 79 Adjuvant Treatment 79 Pivotal Trials 79 Presents Positive 79 Granted Orphan Drug 79 Prolongs Survival 79 Well Tolerated 79 Initiates Phase II 79 FDA Accepts 79 Novel Antibiotic 79 Submits NDA 79 Dose Ranging Study 79 Prospective Randomized 79 Pooled Analysis 79 Novel Oral 78 Patient Enrolment 78 Phase IIa Clinical Trial 78 Initiate Clinical Trial 78 Trial Evaluating 78 Patients Treated 78 Combination Treatment 78 Initiate Phase 78 Initiates Clinical 78 Efficacy Trial 78 Relapsed Multiple Myeloma 78 Investigational Treatment 78 Gout Drug 78 Initiates Clinical Trial 78 Advanced Melanoma 78 IND Application 78 Oral Fingolimod 78 Present Preclinical Data 78 Study Showed 78 Investigational Agent 78 Phase III Pivotal 78 Acute Ischemic Stroke 78 Demonstrates Significant 78 Presents Preclinical Data 78 Pulmonary Arterial Hypertension 78 Metastatic Melanoma 77 Initiates Enrollment 77 Lupus Drug 77 Previously Treated 77 Combination REOLYSIN R 77 FDA Approvals 77 Successfully Completes Phase 77 First Patient Dosed 77 Receives Positive Opinion 77 First Patient Enrolled 77 Investigational Drug 77 Shows Promising 77 Osteoporosis Drug 77 Hsp# Inhibitor 77 Generic Version 77 Migraine Drug 77 Initiate Phase III 77 Pharmacokinetic Study 77 Initiates Clinical Trials 77 Anticancer Drug 77 Demonstrates Efficacy 77 Renal Cell Carcinoma 77 IND Filing 77 Improves Outcomes 77 Transdermal Patch 77 Protease Inhibitor 77 Lung Cancer Trial 77 Testosterone Gel 77 Receives Approvable Letter 77 Randomized Phase 77 Cholesterol Lowering Drug 77 Tezampanel 76 Advanced Prostate Cancer 76 Confirmatory Phase 76 Achieves Primary Endpoint 76 Oral Calcitonin 76 Clinical Study 76 Fast Track Status 76 Metastatic Colorectal Cancer 76 Rheumatoid Arthritis Patients 76 Hormone Refractory Prostate Cancer 76 Long Term Efficacy 76 Randomized Double Blind 76 Mylan Receives Approval 76 Disease Progression 76 Files Investigational 76 Adjunctive Therapy 76 Randomized Clinical Trial 76 Lung Cancer Drug 76 Zoledronic Acid 76 Double Blind Placebo 76 Severe Sepsis 76 Resistant Hypertension 76 Ranolazine 76 HCV Protease Inhibitor 76 Topline Results 76 Controlled Study 76 Anti Tumor Activity 76 Statistically Significant 76 Chronic Hepatitis B 76 Drug Fails 76 Is Well Tolerated 75 Complicated Skin 75 Appears Safe 75 Pafuramidine 75 Epilepsy Drug 75 Survival Benefit 75 Patients Enrolled 75 Glatiramer Acetate 75 Placebo Controlled Trial 75 Presents Preclinical 75 Postmenopausal Osteoporosis 75 Milestone Payment 75 Treated Patients 75 Improved Survival 75 Randomized Study 75 Controlled Trial 75 Unfractionated Heparin 75 Dose Escalation 75 Drug Shows Promise 75 Overactive Bladder 75 Metastatic Prostate Cancer 75 Initiates Phase 75 Antitumor Activity 75 Fondaparinux 75 JAK2 Inhibitor 75 HDAC Inhibitor 75 FOLOTYN ® 75 Seasonal Influenza Vaccine 75 Demonstrates Potent 75 Recombinant Human 75 Relapsing Multiple Sclerosis 75 Expanded Indication 75 Treating Chronic 75 Significantly Improves 75 Fungal Infections 75 Randomized Phase II 75 Receives Milestone Payment 75 Combination Therapy 75 Elderly Patients 75 Commences Phase 75 Adjuvant Therapy 75 Arthritis Drug 75 Study Demonstrates 75 Significantly Improved 75 Clinical Study Shows 75 Phase 2a Study 75 Prostate Cancer Vaccine 74 Newly Diagnosed Multiple Myeloma 74 Microplasmin 74 FDA Clears 74 Bazedoxifene 74 Vaccine Adjuvant 74 Shows Efficacy 74 Autologous Stem Cell Transplantation 74 Elagolix 74 Preclinical Study 74 Oral Formulation 74 VIVITROL ® 74 Phase III Pivotal Trial 74 Clinical Evaluation 74 Rotavirus Vaccine 74 Confirms Efficacy 74 Therapeutic Vaccine 74 Brentuximab Vedotin SGN 74 Nicotine Vaccine 74 FDA APPROVES 74 Hemodialysis Patients 74 Personalized Immunotherapy 74 Sapacitabine 74 PDUFA Date 74 Spectrum Pharmaceuticals Announces 74 Multicenter Randomized 74 Collaborators Present 74 Receives Orphan Drug 74 FDA Okays 74 Receptor Agonist 74 First Patient Treated 74 Medoxomil 74 Commence Phase 74 Demonstrated Significant 74 Prophylactic Treatment 74 Versus Placebo 74 Kinase Inhibitor 74 FDA Approves 74 Tyrosine Kinase Inhibitor 74 Vicriviroc 74 Prostate Cancer Patients 74 Clinical Trial 74 Proves Effective 74 Inhaled Insulin 74 Treatment Naïve 74 Rheumatoid Arthritis Drug 74 Infected Patients 74 Platelet Inhibition 74 Systemic Delivery 74 Extended Release 74 Teva Provides Update 74 Subgroup Analysis 74 Patients Suffering 74 Cholesterol Drug 73 Biomarker Study 73 Psoriasis Drug 73 Low Dose 73 Clinical Outcome 73 Eluting Stent 73 Universal Flu Vaccine 73 Earns Milestone Payment 73 Hypertensive Patients 73 Patent Covering 73 Begins Dosing 73 Safinamide 73 Schizophrenia Drug 73 Chronic Hepatitis C 73 RNAi Therapeutics 73 Disease Modifying 73 Effectively Treats 73 Anticancer Activity 73 Anti Tumor 73 Receives FDA Clearance 73 Benign Prostatic Hyperplasia 73 Augment TM 73 Initiates Phase 2b 73 Positive Opinion 73 Clinical Trial Data 73 Shows Promise Against 73 Patients Receiving 73 Orphan Status 73 Dupuytren Contracture 73 Interferon Beta 73 Xcytrin R 73 Multiple Ascending Dose 73 Efficacious 73 Diabetic Nephropathy 73 Blood Pressure Drug 73 Oral Insulin 73 Breast Cancer Recurrence 73 Hepatocellular Carcinoma 73 MEK Inhibitor 73 Investigational Oral 73 TM Drug Eluting 73 Bosutinib 73 Novel Inhibitor 73 Phase IIa Trial 73 Advanced Renal Cell 73 Treatment Experienced 73 Molecular Diagnostic Test 73 R lenalidomide 73 Enrolls First 73 Tesetaxel 73 Monoclonal Antibody 73 Ozarelix 73 RNAi Therapeutic 73 Multiple Myeloma Patients 73 Novel Mechanism 73 Intravenous Formulation 73 Data Suggest 73 Heart Failure Patients 73 Demonstrates Sustained 73 Advanced Colorectal Cancer 73 Improve Survival 73 Peginterferon 73 Colorectal Cancer Patients 73 Announces FDA Clearance 73 Demonstrates Potential 73 Drug Combo 73 Stent Restenosis 73 See CLINICAL PHARMACOLOGY 72 Receives Fast Track 72 Adjuvant Chemotherapy 72 Relapsing Remitting Multiple Sclerosis 72 Phase Ib Clinical Trial 72 Sirolimus Eluting Stent 72 Announces Tentative Approval 72 Postmenopausal Women 72 Dasatinib 72 Anticancer Compound 72 Generic Versions 72 SPRYCEL ® 72 Advanced Pancreatic Cancer 72 Cutaneous T 72 Significantly Reduced 72 Submits Biologics License Application 72 Treatment Reduces 72 HER2 Positive Breast Cancer 72 Osteoporosis Treatment 72 Demonstrate Significant 72 Lupus Nephritis 72 Metastatic Renal Cell Carcinoma 72 PRN FDA Approves 72 Antiviral Activity 72 IIa Clinical Trial 72 Interferon Alpha 72 Brain Metastases 72 Randomized Double blind 72 Statin Therapy 72 Hypercholesterolemia 72 Inhalation Solution 72 Inhalation Aerosol 72 Shows Promise 72 Gastric Cancer 72 oral prodrug 72 Develop Novel 72 Myelodysplastic Syndromes 72 Kidney Transplant Patients 72 Reports Preclinical Data 72 Naive Patients 72 Acute Heart Failure 72 Novel Compound 72 Interferon Gamma 72 Announces Poster Presentations 72 Fabry Disease 72 Initiate Phase II 72 Replacement Therapy 72 Recurrent Breast Cancer 72 Fracture Risk 72 Sangamo BioSciences Announces 72 Pharmacokinetics PK 72 Plaque Psoriasis 72 Immunomedics Announces 72 GATTEX TM 72 Enrolling Patients 72 REG1 Anticoagulation System 72 Melphalan 72 C1 Inhibitor 72 Phase IIIb 72 Enzyme Replacement Therapy 72 Diabetic Patients 72 Parathyroid Hormone 72 Telbivudine 72 Immunotherapeutic 72 Immunosuppressant 72 Vascular Disrupting Agent 72 phase IIb trial 72 Pediatric Patients 72 Inhaled Corticosteroids 72 Orally Active 72 Mouse Model 72 Plus Ribavirin 72 Tipranavir 72 LibiGel ® 72 Glufosfamide 72 Knee Osteoarthritis 72 Initiated Phase 72 Diabetic Neuropathy 72 Hepatitis C Patients 72 Beta Blocker 72 Valsartan 71 Receives Complete Response 71 Myeloma Patients 71 Shows Statistically Significant 71 Anticancer Agent 71 IL# PE#QQR 71 Symptom Relief 71 Soft Tissue Sarcoma 71 Anti Inflammatory Drug 71 Golimumab 71 FDA Clearance 71 Zenvia Phase III 71 Febuxostat 71 Resubmission 71 Oral Spray 71 Blood Thinner 71 Acute Attacks 71 Drug Eluting 71 FDA Approvable Letter 71 Humanized Anti 71 Significantly Reduces 71 Taro Receives 71 Mycophenolate Mofetil 71 Tiotropium 71 Desvenlafaxine Succinate 71 Cetrorelix 71 Metabolic Efficiency 71 Irinotecan 71 BioElectronics Announces 71 Malaria Vaccine 71 Treatment Naive Patients 71 Lowers Risk 71 Adalimumab 71 Allergic Rhinitis 71 Randomized Evaluation 71 Ischemic Stroke 71 Release Capsules 71 Patients Undergoing 71 HER2 Positive 71 Predict Risk 71 Proven Effective 71 Hormone Receptor Positive 71 Chronic Heart Failure 71 Topical Treatment 71 Combination Clinical Trial 71 fosbretabulin 71 Neoadjuvant Chemotherapy 71 Reveals Positive 71 Venous Thromboembolism 71 ARIXTRA R 71 Stem Cell Treatment 71 Aliskiren 71 Treatment Regimen 71 Tanespimycin 71 Treatment Resistant 71 Potent Antiviral Activity 71 EVIZON TM 71 Atypical Hemolytic Uremic Syndrome 71 Inflammatory Arthritis 71 Radical Prostatectomy 71 Successfully Treated 71 Milestone Payment From 71 Renal Cancer 71 Civacir 71 Relapsed Refractory 71 Acute Myocardial Infarction 71 Aztreonam Lysine 71 Vaginal Gel 71 Delayed Release 71 Peginterferon Alfa 2a 71 Previously Untreated 71 Dose Finding 71 Capsules CII 71 Hematological Malignancies 71 Non Inferiority 71 Aflibercept 71 Regenerative Cells 71 Diabetic Macular Edema 71 Improve Outcomes 71 Diabetic Foot Ulcer 71 Randomised Trial 71 Antitumor 71 Zorbtive TM 71 Gene Therapy Trial 71 Vaccine Candidate 71 Randomized Controlled 71 Multicenter 71 Node Positive 71 Refractory Hodgkin Lymphoma 71 Phase Ib II 71 Sustained Reduction 71 Methylnaltrexone 71 Carotid Stenting 71 Receives Marketing Authorization 71 Chronic Myeloid Leukemia 71 Calcitonin 71 Carboplatin Paclitaxel 71 Testosterone Patch 71 Viral Suppression 71 Ambrisentan 71 Cardiovascular Events 71 Chronic Sinusitis 71 Toremifene 71 Oral Anticoagulant 71 Tesamorelin 71 Randomized Trials 71 Reduces Risk 71 Cervical Cancer Vaccine 71 Fixed Dose 71 Late Breaker 71 Trodusquemine MSI 71 Liver Metastases 71 Eszopiclone 71 Therapeutic Potential 71 Bivalirudin 70 oral dual endothelin 70 Schizophrenia Treatment 70 Targeted Therapies 70 TRANSDUR ™ 70 Dose Ranging 70 Gets FDA Clearance 70 Sagent Pharmaceuticals Announces 70 Oral Mucositis 70 Phase IIIb clinical 70 Neuroprotective Effects 70 Bipolar Depression 70 TO AVOID PREGNANCY WHILE 70 Shown Effective 70 Stent Implantation 70 Ridaforolimus 70 Completes Patient Enrolment 70 Hepatitis C Genotype 70 methylnaltrexone bromide 70 Icatibant 70 Supplemental Biologics License Application 70 Small Molecule 70 Reduces Pain 70 Post Operative 70 Vitrasert R 70 Mg Usa 70 Premature Infants 70 Synthetic Peptide 70 KRN# 70 Eculizumab 70 Reduced Incidence 70 Kamada AAT 70 Marketing Authorisation Application 70 Immunosuppression 70 Romidepsin 70 Tocilizumab 70 Slow Progression 70 Ocrelizumab 70 Slows Progression 70 VIVUS Announces 70 Degarelix 70 Renal Function 70 Interferon beta 1a 70 Nuvelo Announces 70 Patient Outcomes 70 Androgen Deprivation Therapy 70 Telaprevir VX 70 Cethromycin 70 Weight Loss Drug 70 Nilotinib 70 MKC# MKC# PP 70 PHASE III 70 Treating Heart Failure 70 Betaferon R 70 Azacitidine 70 Tumor Growth 70 Pirfenidone 70 Placebo Controlled 70 BioSante Pharmaceuticals Announces 70 Tolerability 70 Orphan Drug Status 70 Sirolimus Eluting 70 lexidronam injection 70 Efficacy Results 70 Malignant Melanoma 70 investigational humanized monoclonal antibody 70 topically applied SEPA 70 Prostate Cancer Treatment 70 Bone Mineral Density 70 Sustained Release 70 NICE Recommends 70 Inflammatory Markers 70 Breast Cancer Treatment 70 Randomized Double Blind Placebo 70 PROSTASCINT R 70 Drug Eluting Stents 70 Combo Therapy 70 Multicenter Phase 70 Erectile Dysfunction Drug 70 Drug Eluting Stent 70 Cholesterol Drugs 70 Less Invasive 70 Tigecycline 70 Clinical Efficacy 70 Begin Clinical Trials 70 Hepatitis B Vaccine 70 Skeletal Muscle 70 Ciclesonide 70 Receives SFDA Approval 70 Submits Supplemental 70 Recurrent Glioblastoma 70 Transdermal Delivery 70 Presents Positive Preclinical 70 Diabetic Neuropathic Pain 70 Cites Positive 70 Treat Anemia 70 FDA Approval 70 Osteoarthritis Patients 70 Secondary Hyperparathyroidism 70 Cardiovascular Outcomes 70 pralatrexate injection folate analogue 70 Stent Thrombosis 70 ORENCIA ® 70 GRAS Status 70 Sustained Efficacy 70 TKB# 70 Pneumococcal Vaccine 70 Enlarged Prostate 70 Systemic Sclerosis 70 Androxal TM 70 Epoetin Alfa 70 Archexin 70 FDA Panel Recommends 70 Smallpox Vaccine 70 Castration Resistant Prostate Cancer 70 Lung Cancer Patients 70 ThermoDox R 70 Preclinical Evaluation 70 Antidepressant Drug 70 Lubiprostone 70 Romiplostim 70 By JENNIFER LEARN 70 Paroxysmal Atrial Fibrillation 70 Dapagliflozin 70 Iloperidone 70 Partial Onset Seizures 70 PEGylated anti 70 Drug Eluting Coronary Stent 70 Drug Resistant 70 BARACLUDE R 70 Invasive Fungal Infections 70 Dalbavancin 70 Bepreve TM 70 Liposomal 70 Ondansetron Injection USP 70 Renal Impairment 70 Ebola Vaccine 70 Levoleucovorin 70 Atopic Dermatitis 70 Ovarian Cancer Patients 70 Chemotherapy Induced Anemia 70 Submits Response 70 Nebulized 70 Prognostic Significance 70 Cardiotoxicity 70 Treatment Naive 70 miconazole Lauriad ® 70 SUTENT ® 70 Bone Metastases 70 FUSILEV ® 70 Neoadjuvant 70 Osteoporosis Drugs 70 Topical Gel 70 STELARA TM 70 Insulin Glargine 70 Myocet 69 Catheter Ablation 69 dependent kinase inhibitor 69 Placebo Controlled Study 69 Pharmaceuticals Initiates 69 Artery Disease 69 Kidney Function 69 Total Knee Arthroplasty 69 Avian Flu Vaccine 69 Randomized Clinical Trials 69 Percutaneous Tibial Nerve Stimulation 69 Beneficial Effects 69 Reduced Risk 69 Completes Dosing 69 PEGINTRON TM 69 Lung Cancer Survival 69 CYT# potent vascular disrupting 69 Acute Coronary Syndromes 69 Nymox NX 69 Dual Antiplatelet Therapy 69 Factor Xa Inhibitor 69 Tacrolimus 69 Anti Clotting Drug 69 Paclitaxel Carboplatin 69 lucinactant 69 Increases Risk 69 Therapy Reduces 69 Kidney Transplant Recipients 69 rasagiline tablets 69 Clostridium difficile Infection 69 Uterine Fibroid Embolization 69 Calcium Acetate 69 Hormone Therapy 69 Enoxaparin 69 Ecallantide 69 Pegloticase 69 Chemoradiation 69 candidates Azedra 69 Extended Release Capsules 69 Therapy Improves 69 Solid Tumors 69 Acute Migraine 69 CCX# B 69 Cloretazine ® 69 Double Blind Randomized 69 Pandemic Influenza Vaccine 69 Patient Accrual 69 Advanced Ovarian Cancer 69 Novel Therapeutic 69 Randomized Controlled Trials 69 Preclinical Efficacy 69 Receptor Antagonist 69 Cancer Treatments 69 Drug Eluting Stent System 69 Pazopanib 69 mGluR5 negative 69 Proton Pump Inhibitor 69 INSPIRE Trial Phase III 69 Inhaled Nitric Oxide 69 Oral Cladribine 69 Topical Cream 69 non nucleoside inhibitor 69 Amrubicin 69 Chemotherapy Regimen 69 Pivotal Phase II 69 Maleate 69 Liver Failure 69 Lung Cancers 69 Localized Prostate Cancer 69 Maribavir 69 initiated Phase Ib 69 Receives Tentative Approval 69 Endovascular Treatment 69 PEGylated Fab fragment 69 Inhaled Liposomal Ciprofloxacin 69 Receive Milestone Payment 69 Gentium Announces 69 Ofatumumab 69 Anemia Drug 69 Diabetic Ulcers 69 Dyloject TM 69 pharmacokinetic PK study 69 Announces Initiation 69 Estrogen Therapy 69 AAG geldanamycin analog 69 Synta Announces 69 Generic Version Of 69 Multicenter Study 69 Luveniq 69 Radiofrequency Ablation 69 Milestone Payments 69 Polymerase Inhibitor 69 Patient Treated 69 FDA Approves Drug 69 Antiviral Drugs 69 Formoterol 69 Aloxi ® 69 Phospholipase A2 69 Vaccine Protects Against 69 Phase IIB 69 acyclovir Lauriad R 69 budesonide foam 69 Granulocyte Colony Stimulating Factor 69 Bare Metal Stents 69 Dose Response 69 Therapeutic Antibody 69 HepaSphere 69 Cell Lymphoma 69 interferon gamma 1b 69 Inhibits 69 phase IIa 69 Bare Metal Stent 69 Diuretic 69 Blinatumomab 69 registrational trial 69 Severe Asthma 69 brand ciclesonide HFA 69 evaluating tivozanib 69 Apaziquone 69 Receives CE Marking 69 Obese Patients 69 Announce License Agreement 69 Montelukast 69 Sevelamer 69 Submits IND 69 SABER ™ 69 Interferon Alfa 69 Seasonal Allergic Rhinitis 69 Meta Analysis 69 Left Ventricular 69 Left Atrial 69 Posaconazole 69 R Saizen R 69 Cypher Sirolimus 69 Metabolic Disorder 69 Iluvien ® 69 Vertebral Fracture 69 Gene Variant 69 dual endothelin receptor antagonist 69 Intravitreal 69 Aurora Kinase 69 Successfully Treats 69 Minimally Invasive Treatment 69 including eniluracil ADH 69 Fewer Side Effects 69 Multicenter Trial 69 includes TOLAMBA TM 69 Critical Limb Ischemia 69 Asthma Treatment 69 LENALIDOMIDE 69 Prodrug 69 albiglutide 69 Poster Presentations 69 Trandolapril 69 Anti CD# Antibody 69 Cocaine Addiction 69 Licenses Novel 69 Therapeutic Efficacy 69 investigational pan BCR 69 Testosterone MDTS ® 69 Epratuzumab 69 targeted radiotherapeutic 69 Mg Uk 69 Study Shows Benefits 69 TRANSDUR ® 69 Antibody Drug Conjugate 69 Refractory Angina 69 SinuNase TM 69 TB Vaccine 69 phase IIb clinical 69 Panzem R 69 Unresectable 69 PROVENGE ® 69 Bevacizumab 69 Prostate AdenoCarcinoma Treatment 69 Antithrombin 69 Demonstrates Statistically Significant 69 vapreotide acetate 69 Hematological Cancers 69 Fulvestrant 69 Anturol TM 69 Atypical Antipsychotic 69 Octreotide 69 Hepatitis C Virus 69 Pegylated 69 Gastrointestinal Stromal Tumors 69 Initiates Dosing 69 Anti Inflammatory 69 Vitro Activity 69 Myelodysplastic Syndrome MDS 69 Drug Prevents 68 PANVAC VF 68 CYPHER R Sirolimus Eluting 68 Clinical Trial Enrollment 68 Trobalt 68 Higher Doses 68 BRIM3 68 molecular imaging radiopharmaceutical 68 rilonacept 68 Cell Transplants 68 atazanavir sulfate 68 Phase Ib study 68 Generic Lovenox 68 Dendritic Cells 68 ANDA Filing 68 Transdermal System 68 alfa 2a 68 Shingles Vaccine 68 Potentially Fatal 68 Chronic Constipation 68 motexafin gadolinium Injection 68 Heart Transplant Recipients 68 sorafenib tablets 68 Hospital Acquired Pneumonia 68 Treatment Shows Promise 68 Non Responders 68 Telithromycin 68 multicenter Phase III 68 TRANSFORMS 68 Endometrial Cancer 68 NAVISTAR R 68 Gene Mutation 68 Oral Laquinimod 68 ALN HPN 68 Follicular Lymphoma 68 selective androgen receptor modulator 68 ELADUR ™ 68 Decitabine 68 2 methoxyestradiol 68 Ziprasidone 68 Dose Escalation Study 68 Capecitabine 68 Chronic Renal Failure 68 Phase III Psoriasis 68 Protease Inhibitors 68 Therapy Shows Promise 68 Tuberculosis Vaccine 68 Endeavor Drug Eluting 68 Receives Positive 68 Oral Contraceptive 68 Soriatane 68 CRMD# 68 sapropterin dihydrochloride 68 Immunomodulatory 68 Abstract Accepted 68 Reports Positive 68 Levels Linked 68 Abciximab 68 Pertuzumab 68 Test Detects 68 Panzem R NCD 68 Bucindolol 68 ODT metoclopramide HCl PEPCID 68 Certolizumab 68 Kidney Transplants 68 Randomized Phase III 68 phase IIa clinical 68 Adenoma 68 Daptomycin 68 HCl Injection 68 Forodesine HCl 68 Announces Publication 68 Therapy Evaluation 68 Smooth Muscle 68 Teriparatide 68 dasatinib Sprycel ® 68 Premenopausal Women 68 novel VDA molecule 68 Novolimus 68 Drug Coated Stent 68 receptor tyrosine kinase inhibitor 68 Cerebril TM 68 Phase IIA 68 BRILINTA 68 Contrast Agent 68 Tumor Targeting 68 Wound Dressing 68 Varespladib 68 Statin Drugs 68 Optimer Pharma 68 Emerging Therapies 68 Complete Remission 68 STRIDE PD 68 Saquinavir 68 ARRY # 68 Ovarian Cancer Treatment 68 Anticoagulant 68 Phase 1b trial 68 Prospective Multicenter 68 ritonavir boosted 68 ENDEAVOR IV 68 Anthracycline 68 Traficet EN 68 Influenza Vaccine Production 68 Migraine Treatment 68 Chronic Lymphocytic Leukemia 68 Insulin Resistance 68 Intracranial Aneurysms 68 Reduces Mortality 68 Randomised 68 Bone Fracture 68 investigational antiplatelet agent 68 FDA Orphan Drug 68 Fixed Dose Combination 68 catheter occlusion 68 Denufosol 68 Effective Than 68 Drug Maker 68 Virus Infection 68 TNF Tumor Necrosis Factor 68 Boceprevir 68 Showed Significant 68 Fluorouracil 68 Unstable Angina 68 Diet Pill 68 Acute Decompensated Heart Failure 68 Hedgehog Pathway Inhibitor 68 Attenuates 68 Tablet Formulation 68 ELADUR TM 68 Liver Toxicity 68 RhuDex 68 Prostate Biopsy 68 atypical Hemolytic Uremic Syndrome 68 EntreMed Presents 68 Hepatitis C Treatment 68 Raptiva R 68 DOR BioPharma Announces 68 Bortezomib 68 Telik logo TELINTRA 68 Pralatrexate 68 Aortic Stenosis 68 Blocked Arteries 68 Therapeutic Effects 68 Cardiogenic Shock 68 Significant Improvements 68 Darbepoetin Alfa 68 Restenosis 68 WorldHeart Announces 68 Ophena 68 MKC# 68 Indomethacin 68 candidates Augment ™ 68 Bone Graft 68 AZILECT R 68 Epidermal Growth Factor Receptor 68 Liprotamase 68 Nucleoside

Back to home page